Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials
about
The evolving role of response-adapted PET imaging in Hodgkin lymphomaImmunotoxin - a new treatment option in patients with relapsed and refractory Hodgkin lymphomaBrentuximab vedotin for treatment of relapsed or refractory malignant lymphoma: results of a systematic review and meta-analysis of prospective studiesBrentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers.Brentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia.Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey.Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma.Brentuximab vedotin in the treatment of a patient with refractory Hodgkin disease and Proteus syndrome - a case report and discussionBrentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients.Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program.Should Response-Adapted Therapy Now Be the Standard of Care for Advanced Hodgkin's Lymphoma?Pharmacotherapy of Hodgkin lymphoma: standard approaches and future perspectives.Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era.Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.Increased Efficacy of Brentuximab Vedotin (SGN-35) in Combination with Cytokine-Induced Killer Cells in Lymphoma.Brentuximab vedotin in pretreated Hodgkin lymphoma patients: a systematic review and meta-analysis.A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma.New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience.Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho-proliferative disorders: a single centre experience.Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients.CD30-positive malignant lymphomas: time for a change of management?Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin.Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma.Long-term follow-up of allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma.Brentuximab vedotin: clinical updates and practical guidance.Management of Hodgkin lymphoma in the era of brentuximab vedotin: real-world data from five European countries.Classical Hodgkin lymphoma primary refractory to brentuximab vedotin, with transformation to CD30-positive diffuse large B-cell lymphoma.Successful treatment of primary bone marrow Hodgkin lymphoma with brentuximab vedotin: a case report and review of the literature.
P2860
Q26750993-92EE4298-4CC3-4964-AAE0-0787F13045B3Q26772848-AD6BA05C-5A15-4787-8B37-7729679FE4D4Q28087540-F8E16CDD-3979-4575-AA15-5DFD9564DE2DQ33420273-7649189B-E2C3-4666-B1E6-B11E31C8107EQ34337660-594E3369-A86A-4AB1-AB20-0FB92B4DD7ECQ35050554-36750A7B-1FE0-43C9-8C70-4784349BDE89Q35223221-79AE3A3A-E189-4637-A924-1E3E317432B4Q35924909-8642C892-5ECD-4195-B912-7B30E57E2A68Q36371623-3374593D-75B6-4A11-B179-F961324B873CQ37216260-D914F0FE-18FF-40BE-8237-17D164337C69Q37694536-0C08D624-FD83-4BEB-B8CB-827EB8EB0496Q38205880-FA84CCB0-08AE-4B23-B7BE-748F94D3FAEAQ38361620-851634C1-536E-4359-B9D2-2CA2C3A62A10Q38664909-4856FE14-3757-4D67-9F9A-0F2D3C1EF393Q38759986-35238810-6CE8-4AF3-B760-8013BB9F6E23Q38812806-089DC00F-1420-42F7-845C-C3933DD9E32CQ38824046-F6F47656-7826-4D29-A2AE-3EF477C17DC0Q38896683-FFBF44B6-1EFD-4B44-BB0D-EE90F55FE9DFQ38951604-9FE4DA3E-3C56-4899-86DE-8A427436844EQ39155963-545094A1-9A48-4B34-A373-23AF25862956Q39530535-9C29B77C-5F18-4FBC-8F6F-D8F9E74BCD9EQ43065863-20D40BD8-5CDB-4174-A677-1D9875F0A6FAQ46698290-DA432F96-710F-498C-A0F2-D453DAF6CC9FQ47130656-9332DDFE-A142-41EE-80B0-74F3D48445F5Q48328423-9A0E90AC-17F8-4F41-9F0B-BB95F8A45B3DQ49282959-6F109779-A05A-429E-BCED-CE8E807C6F6FQ50044569-BA88716E-EB3B-4CD5-B4AE-56D8ED6777D1Q53786443-66E201B6-F04B-495B-9B06-43861DE9446AQ55317504-14D92CFC-B7B2-4A8E-96B8-EBE7429A9FDA
P2860
Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 May 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Brentuximab vedotin in relapse ...... actice outside clinical trials
@en
Brentuximab vedotin in relapse ...... ctice outside clinical trials.
@nl
type
label
Brentuximab vedotin in relapse ...... actice outside clinical trials
@en
Brentuximab vedotin in relapse ...... ctice outside clinical trials.
@nl
prefLabel
Brentuximab vedotin in relapse ...... actice outside clinical trials
@en
Brentuximab vedotin in relapse ...... ctice outside clinical trials.
@nl
P2093
P2860
P50
P1433
P1476
Brentuximab vedotin in relapse ...... actice outside clinical trials
@en
P2093
Alessandro M Gianni
Antonella Anastasia
Armando Santoro
Barbara Botto
Cinzia Pellegrini
Ercole Brusamolino
Francesco Zaja
P2860
P304
P356
10.3324/HAEMATOL.2012.083048
P50
P577
2013-05-03T00:00:00Z